MicroRNA‑375 inhibits oral squamous cell carcinoma cell migration and invasion by targeting platelet‑derived growth factor‑A

Cao,Zheng‑Hao; Cheng,Jing‑Liang; Zhang,Yong; Bo,Chun‑Xiao; Li,Yan‑Liang

doi:10.3892/mmr.2016.6057

MicroRNA‑375 inhibits oral squamous cell carcinoma cell migration and invasion by targeting platelet‑derived growth factor‑A

Authors:
- Zheng‑Hao Cao
- Jing‑Liang Cheng
- Yong Zhang
- Chun‑Xiao Bo
- Yan‑Liang Li
View Affiliations

Affiliations: Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: December 19, 2016 https://doi.org/10.3892/mmr.2016.6057
Pages: 922-928

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA‑375 (miR‑375) serves an important role in cancer development and growth. However, little is known about the role of miR‑375 in the regulation of oral squamous cell carcinoma (OSCC) metastasis and invasion. The present study measured the expression levels of miR‑375 in Tca8113, UM2, UM1 and CAL‑27 cell lines, using reverse transcription‑quantitative polymerase chain reaction. The results demonstrated that miR‑375 expression levels were significantly reduced in UM1 and CAL‑27 (highly metastatic) compared with Tca8113 and UM2 (less aggressive) OSCC cell lines. Furthermore, it was revealed that overexpression of miR‑375 suppressed the migration and invasion of UM1 cells. Based on a luciferase reporter assay, platelet‑derived growth factor‑A (PDGF‑A) was identified as a direct target gene of miR‑375. Additionally, overexpression of PDGF‑A significantly reversed the effect of miR‑375 on cell migration and invasion in UM1 cells. These data demonstrated that miR‑375 suppressed OSCC cell migration and invasion by targeting PDGF‑A, which may be a potential therapeutic target for the treatment of OSCC.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Gupta S, Kong W, Peng Y, Miao Q and Mackillop WJ: Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
3	Wikner J, Gröbe A, Pantel K and Riethdorf S: Squamous cell carcinoma of the oral cavity and circulating tumour cells. World J Clin Oncol. 5:114–124. 2014. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP and Chen CZ: Micromanagers of gene expression: The potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 5:396–400. 2004. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death and tumorigenesis. Br J Cancer. 94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
7	Winther M, Alsner J, Tramm T, Baeksgaard L, Holtved E and Nordsmark M: Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer. Acta Oncol. 54:1582–1591. 2015. View Article : Google Scholar : PubMed/NCBI
8	Hu A, Huang JJ, Xu WH, Jin XJ, Li JP, Tang YJ, Huang XF, Cui HJ, Sun GB, Li RL, et al: miR-21/miR-375 ratio is an independent prognostic factor in patients with laryngeal squamous cell carcinoma. Am J Cancer Res. 5:1775–1785. 2015.PubMed/NCBI
9	Mao Q, Quan T, Luo B, Guo X, Liu L and Zheng Q: miR-375 targets KLF4 and impacts the proliferation of colorectal carcinoma. Tumour Biol. 37:463–471. 2016. View Article : Google Scholar : PubMed/NCBI
10	Jia L, Huang Y, Zheng Y, Lyu M, Zhang C, Meng Z, Gan Y and Yu G: miR-375 inhibits cell growth and correlates with clinical outcomes in tongue squamous cell carcinoma. Oncol Rep. 33:2061–2071. 2015.PubMed/NCBI
11	Song L, Liu S, Zeng S, Zhang L and Li X: miR-375 modulates radiosensitivity of HR-HPV-positive cervical cancer cells by targeting UBE3A through the p53 pathway. Med Sci Monit. 21:2210–2217. 2015. View Article : Google Scholar : PubMed/NCBI
12	Shi W, Yang J, Li S, Shan X, Liu X, Hua H, Zhao C, Feng Z, Cai Z, Zhang L, et al: Potential involvement of miR-375 in the premalignant progression of oral squamous cell carcinoma mediated via transcription factor KLF5. Oncotarget. 6:40172–40185. 2015.PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Yu X and Li Z: MicroRNA expression and its implications for diagnosis and therapy of tongue squamous cell carcinoma. J Cell Mol Med. 20:10–60. 2016. View Article : Google Scholar : PubMed/NCBI
15	Xu H, Yang Y, Zhao H, Yang X, Luo Y, Ren Y, Liu W and Li N: Serum miR-483-5p: A novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma. Tumour Biol. 37:447–453. 2016. View Article : Google Scholar : PubMed/NCBI
16	Saad MA, Kuo SZ, Rahimy E, Zou AE, Korrapati A, Rahimy M, Kim E, Zheng H, Yu MA, Wang-Rodriguez J and Ongkeko WM: Alcohol-dysregulated miR-30a and miR-934 in head and neck squamous cell carcinoma. Mol Cancer. 14:1812015. View Article : Google Scholar : PubMed/NCBI
17	Yoon AJ, Wang S, Shen J, Robine N, Philipone E, Oster MW, Nam A and Santella RM: Prognostic value of miR-375 and miR-214-3p in early stage oral squamous cell carcinoma. Am J Transl Res. 6:580–592. 2014.PubMed/NCBI
18	Siow MY, Ng LP, Vincent-Chong VK, Jamaludin M, Abraham MT, Rahman ZA Abdul, Kallarakkal TG, Yang YH, Cheong SC and Zain RB: Dysregulation of miR-31 and miR-375 expression is associated with clinical outcomes in oral carcinoma. Oral Dis. 20:345–351. 2014. View Article : Google Scholar : PubMed/NCBI
19	Katano M, Nakamura M, Fujimoto K, Miyazaki K and Morisaki T: Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg. 227:365–371. 1998. View Article : Google Scholar : PubMed/NCBI
20	Jones AC, Antillon KS, Jenkins SM, Janos SN, Overton HN, Shoshan DS, Fischer EG, Trujillo KA and Bisoffi M: Prostate field cancerization: Deregulated expression of macrophage inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A (PDGF-A) in tumor adjacent tissue. PLoS One. 10:e01193142015. View Article : Google Scholar : PubMed/NCBI
21	Mishra A, Ormerod AK, Cibull ML, Spear BT, Kraner SD and Kaetzel DM: PDGF-A promoter and enhancer elements provide efficient and selective antineoplastic gene therapy in multiple cancer types. Cancer Gene Ther. 16:298–309. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yu G, Zhou A, Xue J, Huang C, Zhang X, Kang SH, Chiu WT, Tan C, Xie K, Wang J and Huang S: FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway. Oncotarget. 6:11281–11294. 2015. View Article : Google Scholar : PubMed/NCBI